Methods and systems for determination of flow parameters of administered fluid from a radioembolization delivery device may include translationally moving a device delivery arm of the radioembolization delivery device in a translational direction, wherein the device delivery arm is coupled to a syringe holder such that move in the translational direction one of proximally or distally advances the syringe holder; sensing, via one or more pattern sensors, a corresponding movement of a pattern associated with the translational device delivery arm movement as a sensed pattern movement; generating, via the one or more pattern sensors, one or more output signals based on the sensed pattern movement; and generating, via a processor, a flow rate of the administered fluid, a flow amount of the administered fluid, and/or the translational direction of movement of the device delivery arm with respect to the syringe holder based on the one or more

The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Compositions which comprise a gold nanoparticle, dithiolated diethylenetriamine pentaacetic acid (DTDTPA), and a thioctic acid terminated peptide, wherein the DTDTPA is directly linked to the gold nanoparticle surface via an AuS bond, and wherein the thioctic acid terminated peptide is directly linked to the gold nanoparticle surface via an AuS bond.

The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.

The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

In the present disclosure, embodiments of dual-stage syringes are disclosed along with delivery systems incorporating the dual-stage syringes. Embodiments of the dual-stage syringes described herein include sleeved dual-stage syringes, turn-key dual-stage syringes and dual-stage syringes including one or more one-way valves.

In the present disclosure, embodiments of microbead containment systems and containment methods are disclosed. The microbead containment system may include a microsphere container, which includes walls that define a containment space in the microsphere container, and microspheres within the containment space. The walls may include at least one magnetic component configured to produce a magnetic field within the containment space. The microspheres may include a diamagnetic material. The method of containing radioactive microspheres may include loading a plurality of microspheres comprising a diamagnetic material in a container comprising one or more magnetic components. The microspheres contained in the microsphere container interact with the magnetic field in a manner that prevents direct contact of the microspheres and the microsphere container.